Everything below concerns HGF/c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
=== 2019 revision of the SI === Before the 2019 revision of the SI, the mole was defined as the amount of substance of a system that contains as many elementary entities as there are atoms in 12 grams of carbon-12 (the most common isotope of carbon). The term gram-molecule was formerly used to mean one mole of molecules, and gram-atom for one mole of atoms. For example, 1 mole of MgBr2 is 1 gram-molecule of MgBr2 but 3 gram-atoms of MgBr2. In 2011, the 24th meeting of the General Conference on Weights and Measures (CGPM) agreed to a plan for a possible revision of the SI base unit definitions at an undetermined date. On 16 November 2018, after a meeting of scientists from more than 60 countries at the CGPM in Versailles, France, all SI base units were defined in terms of physical constants. This meant that each SI unit, including the mole, would not be defined in terms of any physical objects but rather they would be defined by physical constants that are, in their nature, exact. Such changes officially came into effect on 20 May 2019. Following such changes, "one mole" of a substance was redefined as containing "exactly 6.02214076×1023 elementary entities" of that substance.
== Trends in outbreaks of produce-related illness == An analysis of 3,500 food-poisoning outbreaks between 1990 and 2003 found that contaminated produce was responsible for the greatest number of individual foodborne illnesses. The study, by the Center for Science in the Public Interest, found that produce caused 428 outbreaks and 23,857 cases of illness. Authorities note that several factors have contributed to the rise in outbreaks:
=== 1970s === The scientific and medical markets have always been important for Edwards. The introduction of X-ray technology required the use of a vacuum. Vacuum technology also played an important role in the development of neuroimaging (brain scanners), like MRI, CT, and PET scanners. The first home computers were brought to the market in the 1970s and the development of computer technology has been unstoppable ever since. The mass production of CRT displays and integrated circuits necessitated electronic companies to scale up, with vacuum installations becoming bigger and demand for vacuum purity increasing. In the 1970s, Edwards Vacuum also collaborated with Seiko Seiki for the invention of magnetically suspended turbopumps. These molecular turbopumps use magnetically levitated bearings, which eliminate the risk of vacuum contamination, require less maintenance, and feature lower noise and vibration levels. This type of technology is particularly suitable for scientific applications and the harsh processes in semiconductor manufacturing. The newly emerged dry pumps and turbomolecular pumps supported innovation in the scientific instrument markets over the next couple of decades. The scientific instrument market is now the second biggest market for Edwards Vacuum, after the semiconductor and electronics industry.
Radio Frequency Identification (RFID) – identification tags containing a tiny radio transponder (receiver and transmitter) which are attached to merchandise. When it receives an interrogation pulse of radio waves from a nearby reader unit, the tag transmits back an ID number, which can be used to inventory goods. Passive tags, the most common type, have a chip powered by the radio energy received from the reader, rectified by a diode, and can be as small as a grain of rice. They are incorporated in products, clothes, railroad cars, library books, airline baggage tags and are implanted under the skin in pets and livestock (microchip implant) and even people. Privacy concerns have been addressed with tags that use encrypted signals and authenticate the reader before responding. Passive tags use 125–134 kHz, 13, 900 MHz and 2.4 and 5 GHz ISM bands and have a short range. Active tags, powered by a battery, are larger but can transmit a stronger signal, giving them a range of hundreds of meters. Submarine communication – When submerged, submarines are cut off from all ordinary radio communication with their military command authorities by the conductive seawater. However radio waves of low enough frequencies, in the VLF (30 to 3 kHz) and ELF (below 3 kHz) bands are able to penetrate seawater. Navies operate large shore transmitting stations with power output in the megawatt range to transmit encrypted messages to their submarines in the world's oceans. Due to the small bandwidth, these systems cannot transmit voice, only text messages at a slow data rate.
== Delivery vehicles == There are different types of drug delivery vehicles, such as polymeric micelles, liposomes, lipoprotein-based drug carriers, nano-particle drug carriers, dendrimers, etc. An ideal drug delivery vehicle must be non-toxic, biocompatible, non-immunogenic, biodegradable, and must avoid recognition by the host's defense mechanisms[3].
Sources: en.wikipedia.org
== Instrumentation and Performance == Initially the digital ion trap was constructed in form of a 3D ion trap, where the drive signal was fed to the ring electrode of the trap. Instead of scanning up the RF voltage, in the DIT, the frequency of the rectangular waveform signal is scanned down during a forward mass scan. This avoided the high voltage breakdown which set the upper limitation of a mass scan. Mass range of DIT up to 18,000 Th was demonstrated by use of an atmospheric MALDI ion source and was later expanded to cover m/z of a singly charged antibody at about 900,000 Th by Koichi Tanaka etc. The MOSFET switch circuit is responsible to provide the rectangular wave drive signal. The drive circuit of DIT is much compact compared to the RF generator with LC resonator circuit used for conventional sinusoidal wave ion trap. It also provides the capability of fast start up and fast termination of the waveform, which enables injection and ejection of ion with high efficiency. A field adjusting electrode placed adjacent to the entrance end-cap and biased with certain dc voltages helped to achieve good mass resolution for both forward and reverse mass scans, as well as for precursor isolation. With trapping voltage of +/- 1kV, a zoom scan resolving power of 19,000 was demonstrated.
=== Itching === In the classic scenario, the itch is made worse by warmth and is usually experienced as being worse at night, possibly because distractions are fewer. As a symptom, it is less common in the elderly.
There have been several structures solved for this class of enzymes, given PDB accession codes, and published in peer-reviewed journals. At least 4 such structures have been solved using pig enzymes: PDB: 1OHV, PDB: 1OHW, PDB: 1OHY, PDB: 1SF2, and at least 4 such structures have been solved in Escherichia coli: PDB: 1SFF, PDB: 1SZK, PDB: 1SZS, PDB: 1SZU. There are actually some differences between the enzyme structure for these organisms. E. coli enzymes of GABA-T lack an iron-sulfur cluster that is found in the pig model. Amino acid residues found in the active site of 4-aminobutyrate transaminase include Lys-329, which are found on each of the two subunits of the enzyme. This site will also bind with a pyridoxal 5'- phosphate co-enzyme. Aminooxyacetic acid Gabaculine Phenelzine Phenylethylidenehydrazine (PEH) Rosmarinic acid Valproic acid Vigabatrin 4-Aminobutyrate+Transaminase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Pearl PL, Parviz M, Hodgeman R, Gibson KM, Reimschisel T (2015). "GABA-transaminase deficiency". MedLink Neurology.
Like DNA, most biologically active RNAs, including mRNA, tRNA, rRNA, snRNAs, and other non-coding RNAs, contain self-complementary sequences that allow parts of the RNA to fold and pair with itself to form double helices. Analysis of these RNAs has revealed that they are highly structured. Unlike DNA, their structures do not consist of long double helices, but rather collections of short helices packed together into structures akin to proteins. In this fashion, RNAs can achieve chemical catalysis (like enzymes). For instance, determination of the structure of the ribosome—an RNA-protein complex that catalyzes the assembly of proteins—revealed that its active site is composed entirely of RNA.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.